Science

CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

0
CAR T-cell therapy found highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.
Read More

admin

Integrated anemia-SCD test demonstrates accurate results in study at 2020 ASH meeting

Previous article

Study reveals surprising benefit of clonal hematopoiesis in allogeneic transplants

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Science